CCM
Camber Capital Management Portfolio holdings
AUM
$718M
This Quarter Return
+9.09%
1 Year Return
-4.23%
3 Year Return
+26.63%
5 Year Return
+47.71%
10 Year Return
+121.3%
AUM
$1.69B
AUM Growth
+$1.69B
(-2.2%)
Cap. Flow
-$154M
Cap. Flow
% of AUM
-9.12%
Top 10 Holdings %
Top 10 Hldgs %
62.77%
Holding
41
New
5
Increased
5
Reduced
7
Closed
8
Top Buys
| 1 |
BIVV
Bioverativ Inc. Common Stock
BIVV
|
$59.9M |
| 2 |
Sarepta Therapeutics
SRPT
|
$40M |
| 3 |
Gilead Sciences
GILD
|
$27.2M |
| 4 |
Puma Biotechnology
PBYI
|
$24.2M |
| 5 |
ELGX
Endologix Inc
ELGX
|
$17.1M |
Top Sells
| 1 |
Biogen
BIIB
|
$49.6M |
| 2 |
UAM
Universal American Corp
UAM
|
$48.5M |
| 3 |
CONMED
CNMD
|
$33.1M |
| 4 |
ATHN
Athenahealth, Inc.
ATHN
|
$31.6M |
| 5 |
Perrigo
PRGO
|
$26.6M |
Sector Composition
| 1 | Healthcare | 86.79% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Teva Pharmaceuticals
TEVA
$21.1B
| $167M | 6.79% | 5,216,450 +492,000 | +10% | +$15.8M |
|
2
Viatris
VTRS
$12.3B
| $162M | 6.56% | 4,145,889 | – | – |
|
|
3
Gilead Sciences
GILD
$140B
| $129M | 5.23% | 1,900,000 +400,000 | +27% | +$27.2M |
|
4
Nektar Therapeutics
NKTR
$568M
| $127M | 5.14% | 5,400,000 -600,000 | -10% | -$14.1M |
|
|
AGN
5
DELISTED
Allergan plc
AGN
| $104M | 4.22% | 435,750 -107,250 | -20% | -$25.6M |
|
6
Myriad Genetics
MYGN
$593M
| $83M | 3.37% | 4,325,000 +265,000 | +7% | +$5.09M |
|
|
GHDX
7
DELISTED
Genomic Health, Inc.
GHDX
| $77.4M | 3.14% | 2,458,100 | – | – |
|
8
Brookdale Senior Living
BKD
$1.83B
| $73.9M | 3% | 5,500,000 | – | – |
|
9
Vertex Pharmaceuticals
VRTX
$100B
| $71.1M | 2.88% | 650,000 -100,000 | -13% | -$10.9M |
|
10
Select Medical
SEM
$1.61B
| $66.8M | 2.71% | 5,000,000 -1,025,000 | -17% | -$13.7M |
|
|
BIVV
11
DELISTED
Bioverativ Inc. Common Stock
BIVV
| $59.9M | 2.43% | +1,100,000 | New | +$59.9M |
|
12
LivaNova
LIVN
$3.08B
| $58.8M | 2.39% | 1,200,000 | – | – |
|
13
Orthofix Medical
OFIX
$592M
| $57.2M | 2.32% | 1,500,000 | – | – |
|
|
ENDP
14
DELISTED
Endo International plc
ENDP
| $56.4M | 2.29% | 5,052,000 +1,150,000 | +29% | +$12.8M |
|
|
15
Perrigo
PRGO
$3.27B
| $53.7M | 2.18% | 808,200 -400,000 | -33% | -$26.6M |
|
|
CSII
16
DELISTED
Cardiovascular Systems, Inc.
CSII
| $49.5M | 2.01% | 1,750,000 -750,000 | -30% | -$21.2M |
|
17
Abbott
ABT
$231B
| $44.4M | 1.8% | 1,000,000 | – | – |
|
|
ELGX
18
DELISTED
Endologix Inc
ELGX
| $43.4M | 1.76% | 6,000,000 +2,365,000 | +65% | +$17.1M |
|
19
Alkermes
ALKS
$4.78B
| $42.4M | 1.72% | 725,000 -275,000 | -28% | -$16.1M |
|
|
20
Sarepta Therapeutics
SRPT
$1.78B
| $40M | 1.62% | +1,350,000 | New | +$40M |
|
|
NVTA
21
DELISTED
Invitae Corporation
NVTA
| $26.5M | 1.08% | 2,398,123 | – | – |
|
|
ELOS
22
DELISTED
Syneron Medical Ltd
ELOS
| $24.8M | 1% | 2,347,593 | – | – |
|
|
23
Puma Biotechnology
PBYI
$254M
| $24.2M | 0.98% | +650,000 | New | +$24.2M |
|
24
Option Care Health
OPCH
$4.65B
| $17.3M | 0.7% | 10,180,000 | – | – |
|
25
PTC Therapeutics
PTCT
$3.92B
| $12.3M | 0.5% | +1,250,000 | New | +$12.3M |
|